CLINICAL TRIAL: RITUXIMAB IN THE TREATMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 目的：这项研究是为了确定药物利妥昔单抗是否可以减少特发性膜性肾病患者的尿蛋白。利妥昔单抗（也称为Rituxan）是由Genentech，Inc.生产的单克隆抗体。和Biogen IDEC Pharmaceuticals使用重组DNA技术。利妥昔单抗未被批准用于治疗特发性膜性肾病。 参与者：20例膜性肾病（MN）患者将参与本研究。 他们的参与将包括在16个月期间进行18次访问。 操作步骤：这是一项非对照的2期试验，评估利妥昔单抗对20例特发性膜性肾病患者蛋白尿的影响。主要终点是蛋白尿从基线到12个月的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: This study is being done to determine if the medication Rituximab can reduce protein in the urine of patients with idiopathic membranous nephropathy. Rituximab (also called Rituxan¿) is a monoclonal antibody produced by Genentech, Inc. and Biogen IDEC Pharmaceuticals using recombinant DNA technology. Rituximab is not approved to treat idiopathic membranous nephropathy. Participants: Twenty patients with Membranous Nephropathy (MN) will participate in the study. Their participation will consist of 18 visits over a 16-month period. Procedures: This is an uncontrolled, phase 2 trial assessing the effects on proteinuria of Rituximab in 20 patients with idiopathic membranous nephropathy. The primary endpoint is the change in proteinuria from baseline to 12 months.